First human tests for new hepatitis b vaccines show promise
NCT ID NCT05770895
Summary
This early-stage study tested the safety of two new therapeutic vaccines, GS-2829 and GS-6779, in healthy volunteers and people with chronic hepatitis B. The main goal was to see if the vaccines were safe and well-tolerated, and to measure the immune response they triggered against the hepatitis B virus. Participants with hepatitis B had to be on stable antiviral medication and could not stop it during the study.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, 833, Taiwan
-
Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital
Taoyuan, 33305, Taiwan
-
Chia-Yi Christian Hospital
Chiayi City, 60002, Taiwan
-
E-DA Hospital
Kaohsiung City, 82445, Taiwan
-
Kaohsiung Medical University Hospital
Kaohsiung City, 807, Taiwan
-
National Cheng Kung University Hospital
Tainan, 7428, Taiwan
-
National Taiwan University Hospital
Taipei, 100229, Taiwan
-
New Zealand Clinical Research (NZCR)
Auckland, 1010, New Zealand
-
St. Martin De Porres Hospital
Chiayi City, 600, Taiwan
Conditions
Explore the condition pages connected to this study.